The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma


Combination therapy with the oral fluoropyrimidine anticancer drug S1 and interferon is reportedly effective for the treatment of advanced hepatocellular carcinoma (HCC), but selection criteria for this therapy have not been clarified. In this study, we attempted to identify factors predicting the effectiveness of this combination therapy. Pathological… (More)
DOI: 10.1007/s00535-010-0294-5


8 Figures and Tables


Citations per Year

57 Citations

Semantic Scholar estimates that this publication has 57 citations based on the available data.

See our FAQ for additional information.

Slides referencing similar topics